292 related articles for article (PubMed ID: 10069545)
21. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism".
Krystal JH; Gueorguieva R; Cramer J; Collins J; Rosenheck R;
Alcohol Clin Exp Res; 2008 Jan; 32(1):85-91. PubMed ID: 18070245
[TBL] [Abstract][Full Text] [Related]
22. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking.
Hernandez-Avila CA; Song C; Kuo L; Tennen H; Armeli S; Kranzler HR
Alcohol Clin Exp Res; 2006 May; 30(5):860-5. PubMed ID: 16634855
[TBL] [Abstract][Full Text] [Related]
23. Subjective and objective responses to ethanol in moderate/heavy and light social drinkers.
Holdstock L; King AC; de Wit H
Alcohol Clin Exp Res; 2000 Jun; 24(6):789-94. PubMed ID: 10888066
[TBL] [Abstract][Full Text] [Related]
24. 6-beta-naltrexol reduces alcohol consumption in rats.
Rukstalis MR; Stromberg MF; O'Brien CP; Volpicelli JR
Alcohol Clin Exp Res; 2000 Oct; 24(10):1593-6. PubMed ID: 11045869
[TBL] [Abstract][Full Text] [Related]
25. Ondansetron alters human alcohol intoxication.
Swift RM; Davidson D; Whelihan W; Kuznetsov O
Biol Psychiatry; 1996 Sep; 40(6):514-21. PubMed ID: 8879472
[TBL] [Abstract][Full Text] [Related]
26. Targeted naltrexone for early problem drinkers.
Kranzler HR; Armeli S; Tennen H; Blomqvist O; Oncken C; Petry N; Feinn R
J Clin Psychopharmacol; 2003 Jun; 23(3):294-304. PubMed ID: 12826991
[TBL] [Abstract][Full Text] [Related]
27. Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers.
Na C; Lee YS
Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):663-70. PubMed ID: 12188097
[TBL] [Abstract][Full Text] [Related]
28. The subjective and reinforcing effects of visual and olfactory stimuli in alcohol drinking.
Perkins KA; Ciccocioppo M; Jacobs L; Doyle T; Caggiula A
Exp Clin Psychopharmacol; 2003 Nov; 11(4):269-75. PubMed ID: 14599260
[TBL] [Abstract][Full Text] [Related]
29. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Lapham SC; McMillan GP
J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
[TBL] [Abstract][Full Text] [Related]
30. Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers.
Davidson D; Saha C; Scifres S; Fyffe J; O'Connor S; Selzer C
Addict Behav; 2004 Aug; 29(6):1253-8. PubMed ID: 15236831
[TBL] [Abstract][Full Text] [Related]
31. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.
Anton RF; Drobes DJ; Voronin K; Durazo-Avizu R; Moak D
Psychopharmacology (Berl); 2004 Apr; 173(1-2):32-40. PubMed ID: 14722705
[TBL] [Abstract][Full Text] [Related]
32. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
[TBL] [Abstract][Full Text] [Related]
33. Low alcohol alternatives: a promising strategy for reducing alcohol related harm.
Segal DS; Stockwell T
Int J Drug Policy; 2009 Mar; 20(2):183-7. PubMed ID: 18675542
[TBL] [Abstract][Full Text] [Related]
34. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
35. Behavioral consequences of repeated nicotine during adolescence in alcohol-preferring AA and alcohol-avoiding ANA rats.
Kemppainen H; Hyytiä P; Kiianmaa K
Alcohol Clin Exp Res; 2009 Feb; 33(2):340-9. PubMed ID: 19032573
[TBL] [Abstract][Full Text] [Related]
36. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study.
Caputo F; Addolorato G; Stoppo M; Francini S; Vignoli T; Lorenzini F; Del Re A; Comaschi C; Andreone P; Trevisani F; Bernardi M;
Eur Neuropsychopharmacol; 2007 Dec; 17(12):781-9. PubMed ID: 17611081
[TBL] [Abstract][Full Text] [Related]
37. Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol.
Mitchell JM; Bergren LJ; Chen KS; Rowbotham MC; Fields HL
Neurobiol Dis; 2009 Jan; 33(1):72-80. PubMed ID: 18955144
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
[TBL] [Abstract][Full Text] [Related]
39. Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence.
Matzeu A; Terenius L; Martin-Fardon R
Alcohol Clin Exp Res; 2018 Dec; 42(12):2466-2478. PubMed ID: 30320880
[TBL] [Abstract][Full Text] [Related]
40. Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.
Froehlich JC; Fischer SM; Dilley JE; Nicholson ER; Smith TN; Filosa NJ; Rademacher LC
Alcohol Clin Exp Res; 2016 Sep; 40(9):1961-70. PubMed ID: 27469281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
